ZYME Zymeworks Inc.

NASDAQ
$26.45

Zymeworks Inc. (ZYME) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.1% since its last earnings release on November 9, 2026.

Zymeworks Missed Consensus Estimates, Raises Guidance
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs $0.11
Rev est $74.78M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $28.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zymeworks Inc.

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.